Ardelyx Reports Real-World Phosphate Reductions With XPHOZAH Across Phosphate Binder Groups In Dialysis Patients, Presented At The ASN Kidney Week 2026

Real-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosphate binder groups evaluated

Additional data highlighted the challenges of managing hyperphosphatemia and the morbidity and mortality risks associated with long-term elevated phosphorus

WALTHAM, Mass., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced results from a real-world analysis presented at the American Society of Nephrology (ASN) Kidney Week 2026 evaluating real-world serum phosphate outcomes among adults on dialysis who initiated XPHOZAH either without a phosphate binder or as add-on therapy to a single phosphate binder. Ardelyx also presented data on the challenges patients experience in managing hyperphosphatemia, as well as the association between long-term hyperphosphatemia and serious health outcomes in patients on dialysis, including morbidity and mortality.